Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionStem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver InjuryPlasma membrane transporters in modern liver pharmacologyCharacterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical functionFunctional expression of the 11 human Organic Anion Transporting Polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate.Oatp1a1 requires PDZK1 to traffic to the plasma membrane by selective recruitment of microtubule-based motor proteins.Synergistic interaction between genetics and disease on pravastatin dispositionFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.Organic anion-transporting polypeptides.Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis.Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).
P2860
Q24273350-2841E6FD-737E-409C-B10A-8844A3D2D59BQ26781923-1E55F3F4-4460-4A37-B02F-6DA501558E4BQ26829263-E777257D-ECCC-4A94-96DF-B2ABD2777D25Q28537862-27004AFA-6E2C-4706-B2EC-5886FB8FB43FQ30367871-6FB6F1DF-E728-4AC5-8721-E3BED1904706Q30561083-AB066E25-089A-4EDC-9D49-D0E67B2F0CE3Q33786577-0535856A-5B51-41AB-879E-6545DFDC2605Q34646772-1FAF2904-5E33-419D-B498-E533DC9C4E94Q36616448-590024DC-B669-4423-98BB-857D67C1DD87Q36998199-8D9CEA42-61EB-4691-A398-38AD734E06B8Q37603899-1BA53E96-298B-47F7-909E-8A469C6AA7B9Q37663390-25236405-E4D1-40AE-A22F-392147FB3684Q37718185-F6CDBF97-28B5-4382-BCA7-4F832CD6CFF3Q38845004-D1294515-EB88-4DC7-BB29-A75691E60D9FQ55330048-DB07E65C-F007-4484-93C6-0766ABF1DE12
P2860
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetics or environment in dru ...... es and adverse drug reactions.
@en
Genetics or environment in dru ...... es and adverse drug reactions.
@nl
type
label
Genetics or environment in dru ...... es and adverse drug reactions.
@en
Genetics or environment in dru ...... es and adverse drug reactions.
@nl
prefLabel
Genetics or environment in dru ...... es and adverse drug reactions.
@en
Genetics or environment in dru ...... es and adverse drug reactions.
@nl
P2860
P1476
Genetics or environment in dru ...... es and adverse drug reactions.
@en
P2093
John D Clarke
Nathan J Cherrington
P2860
P304
P356
10.1517/17425255.2012.656087
P407
P577
2012-01-27T00:00:00Z